<SEC-DOCUMENT>0000950170-24-059109.txt : 20240514
<SEC-HEADER>0000950170-24-059109.hdr.sgml : 20240514
<ACCEPTANCE-DATETIME>20240514081512
ACCESSION NUMBER:		0000950170-24-059109
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240514
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240514
DATE AS OF CHANGE:		20240514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Candel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001841387
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				522214851
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40629
		FILM NUMBER:		24941543

	BUSINESS ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		617-916-5445

	MAIL ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Candel Therapeutics, Inic.
		DATE OF NAME CHANGE:	20210120
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cadl-20240514.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-13T17:57:04.2969+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:cadl="http://www.candeltx.com/20240514" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_453f6126-d104-4821-863e-978d8da3f7f8" name="dei:EntityCentralIndexKey" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b">0001841387</ix:nonNumeric><ix:nonNumeric id="F_0a59e04b-f099-449e-912f-08e8847957d4" name="dei:AmendmentFlag" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cadl-20240514.xsd"/></ix:references><ix:resources><xbrli:context id="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001841387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-14</xbrli:startDate><xbrli:endDate>2024-05-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43950711-2afa-4c57-ac76-6efba40993c0" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3e1bcc5-28ee-45b6-b282-62743ec17d80" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 14, 2024</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_224be1f4-0e1b-46d7-80bd-3ca5e22e1f78" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">CANDEL THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"/>
    <td style="width:33.333%;"/>
    <td style="width:33.333%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f2f1d5f5-8cff-4007-9e16-a6ef712df647" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_91814a79-7a63-4182-b028-585539629491" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-40629</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_123855ef-0475-4dcb-a756-b8888994bf8f" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">52-2214851</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_cf298595-4374-48d9-811c-d5790679fb58" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">117 Kendrick St</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">., </span><span><ix:nonNumeric id="F_d6d16703-1c40-478c-aad5-f8a0975f724f" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 450</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_869e7d2d-9fd8-4c27-a85f-ccf8d6e88b8a" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Needham</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_5ce5fa7d-209d-4b74-b575-36afccb79b15" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1c2b4fc5-b604-42e5-a9b3-cd0849879894" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02494</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e639482b-4c3e-4915-b0e8-e110dcdc3be1" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(617)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7618bd8b-e01b-406c-b16c-bc08f3f91b57" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">916-5445</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_aaab7e50-fe35-489c-9431-2e671a30291f" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_e5f95926-75b2-4412-bee1-5a11e6590cdb" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_0374c72c-17c3-42fc-8f17-04f79edae212" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_063edc3f-39db-4dfc-98e0-f7dd390b25d6" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c58d815a-2eea-43a3-b229-65227ac33819" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock, $0.01 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_55735ef1-9a82-4523-9f7d-f80e662b9cdc" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CADL</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_055c397e-4c85-4e37-b2d3-d1c73973adae" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6cecfc3-dc62-4683-80d3-3b77b285e224" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f6e3358-f5c2-4154-a4c2-025bb5b64a58" contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 14, 2024, Candel Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is furnished herewith and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.08%;"/>
    <td style="width:2.02%;"/>
    <td style="width:90.9%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;99.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><a href="cadl-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release dated May 14, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.46%;"/>
    <td style="width:5.04%;"/>
    <td style="width:3.04%;"/>
    <td style="width:46.46%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Candel Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 14, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Paul Peter Tak</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Paul Peter Tak, M.D., Ph.D., FMedSci</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cadl-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img160460863_0.jpg" alt="img160460863_0.jpg" style="width:189px;height:84px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Proxima Nova',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics Reports First Quarter 2024 Financial Results</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;min-width:fit-content;">and Recent Corporate Highlights</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">Phase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">On track for topline disease-free survival data from CAN-2409 phase 3 clinical trial in localized intermediate/high risk prostate cancer, expected in Q4 2024</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) &#x2014; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics, Inc. (Candel or the Company)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">(Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201c;It was a catalyst-rich first quarter for Candel, marked by significant advances across both our clinical and preclinical programs,&#x201d; said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. &#x201c;Notably, as our clinical data mature with long-term follow up, we are beginning to observe highly differentiated results in long-term survival of patients treated with our viral immunotherapies. An example of these clinical results was recently shared in an update of the phase 2 randomized clinical trial of CAN-2409 in patients with borderline resectable pancreatic cancer, where a notable improvement in overall survival, in patients treated with CAN-2409 plus standard of care chemoradiation, was demonstrated compared to chemoradiation alone. The FDA granted CAN-2409 both Fast Track Designation and Orphan Drug Designation for treatment of patients with pancreatic ductal adenocarcinoma to improve median overall survival and treatment of pancreatic cancer, respectively, providing steady momentum to advance this promising investigational treatment for patients with significant unmet medical need.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Dr. Tak continued, &#x201c;We are also excited to announce that topline overall survival data from our phase 2 clinical trial of CAN-2409 in patients with stage III/IV non-small cell lung cancer and an inadequate response to immune checkpoint inhibitors will be presented at the upcoming ASCO meeting in Chicago on Monday, June 3, 2024.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201c;In addition to our advances in the clinic, we have made great progress with our enLIGHTEN</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Arial;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> Discovery Platform. In April 2024, we presented our second drug</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">candidate from this platform, a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures, in a late-breaking presentation at the American Association for Cancer Research (AACR) Annual Meeting. We believe this preclinical candidate offers groundbreaking potential in the treatment of cancer,&#x201d; continued Dr. Tak. &#x201c;We expect to release additional preclinical and clinical data in the coming year, consistent with our commitment to innovation and patient care.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">First Quarter 2024 &amp; Recent Highlights</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Program Updates</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">CAN-2409 &#x2013; Pancreatic Cancer</font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">In early April, announced positive updated survival data, from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC).</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:23.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.347372402728684%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Data showed notable improvements in estimated median overall survival (mOS) of 28.8 months after experimental treatment with CAN-2409 versus 12.5 months in control group.</font></div></div>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:23.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.347372402728684%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus 16.7% in the control group after chemoradiation. At 36 months, estimated survival was 47.6% in the CAN-2409 group versus 16.7% in the control group.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:23.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.347372402728684%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">No new safety signals were observed, providing further support that multiple injections of CAN-2409 have been generally well tolerated to date, with no dose-limiting toxicities and no cases of pancreatitis reported.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:23.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.347372402728684%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Previous analysis of resected tumors showed dense aggregates of immune cells, including CD8+, cytotoxic tumor infiltrating lymphocytes and dendritic cells, in PDAC tissue after CAN-2409 administration, confirming activation of a robust antitumoral immune response.</font></div></div>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CAN-2409 for the treatment of pancreatic cancer.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">CAN-2409 &#x2013; Non-small cell lung cancer (NSCLC)</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Announced a poster titled &#x201c;Overall survival after treatment with CAN- 2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with inadequate response to ICI&#x201d; was accepted for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, and will be presented by Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania, on June 3, 2024 in Chicago, IL.  </font></div></div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">CAN-3110 &#x2013; Recurrent High-Grade Glioma (rHGG)</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Received Fast Track Designation from the FDA for CAN-3110 for the treatment of patients with rHGG to improve OS.</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Announced during the 5th Glioblastoma Drug Development Summit in Boston that six patients have been treated with multiple injections (up to six injections) of CAN-3110 in cohort C of the ongoing phase 1b clinical trial, reporting a favorable safety and tolerability profile.</font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Announced a Trial-in-Progress poster, titled &#x201c;Longitudinal stereotactic injections of oncolytic immunoactivating rQNestin34.5v.2 (CAN-3110) with concomitant biopsies for &#x201c;-omic&#x201d; analyses in recurrent glioblastoma (GBM)&#x201d; was accepted for the 2024 ASCO Annual Meeting, and will be presented by David A. Reardon, MD, Professor of Medicine at Harvard Medical School and Clinical Director, Center for Neuro-Oncology at Dana Farber Cancer Institute, on June 1, 2024, in Chicago, IL. </font></div></div>
  <p style="margin-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">enLIGHTEN&#153; Discovery Platform </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.999615998463994%;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Presented preclinical data at the AACR Annual Meeting unveiling the second candidate from the enLIGHTEN&#153; Discovery Platform, a first-in-class multimodal immunotherapy candidate to induce tertiary lymphoid structures (TLS), being developed as a novel therapeutic for solid tumors.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Anticipated Milestones</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Phase 2 topline OS data for CAN-2409 in NSCLC to be presented at ASCO on June 3, 2024</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Updated Phase 1b data (Arm C) for CAN-3110 in rHGG expected in H2 2024</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Phase 2 topline data for CAN-2409 in </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">low-to-intermediate-risk</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">, localized, non-metastatic prostate cancer expected in Q4 2024</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Phase 3 topline disease-free survival data for CAN-2409 in localized </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">intermediate/high-risk</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> prostate cancer expected in Q4 2024</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Financial Results for First Quarter Ended March 31, 2024</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Research and Development Expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> Research and development expenses were $4.1 million for the first quarter of 2024 compared to $5.5 million for the first quarter of 2023. The decrease was primarily due to lower employee-related expenses following the corporate restructuring in the fourth quarter of 2023 and lower clinical development costs driven by a reduction in regulatory costs for CAN-2409 programs. Research and development expenses included non-cash stock compensation expense of $0.6 million for the first quarter of 2024 compared to $0.3 million for the first quarter of 2023.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.259%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">General and Administrative Expenses:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> General and administrative expenses were $3.8 million for the first quarter of 2024 compared to $4.2 million for the first quarter of 2023. The decrease was primarily due to</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">lower employee-related expenses following the corporate restructuring in the fourth quarter of 2023 and lower insurance costs. These decreases were partially offset by increased professional and consulting fees. General and administrative expenses included non-cash stock compensation expense of $0.5 million for the first quarter of 2024 compared to $0.4 million for the first quarter of 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.259%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.009%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Net Loss:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> Net loss for the first quarter of 2024 was $8.2 million, compared to a net loss of $8.8 million for the first quarter of 2023, and included other expense, net of $0.3 million and other income, net $0.8 million, respectively. The change from other income, net in the first quarter of 2023 to other expense, net in the first quarter of 2024 was primarily due to the change in the fair value of the Company&#x2019;s warrant liability and lower interest income.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.009%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Cash Position:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> Cash and cash equivalents, as of March 31, 2024, were $25.7 million, as compared to $35.4 million as of December 31, 2023. Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the fourth quarter of 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">About Candel Therapeutics</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable Pancreatic Ductal Adenocarcinoma PDAC (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1b clinical trial in recurrent high-grade glioma (rHGG). Finally, Candel&#x2019;s enLIGHTEN&#153; Discovery</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">For more information about Candel, visit</font><font style="color:#002060;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">: </font><font style="color:#cc8400;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">www.candeltx.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">This press release includes certain disclosures that contain &#x201c;forward-looking statements,&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, including key data readout milestones and presentations; expectations regarding early biological readouts as predictor of clinical response; expectations regarding the therapeutic benefit of the Company&#x2019;s programs, the ability of CAN-2409 to improve the median overall survival of patients with PDAC; the ability of CAN-3110 to improve the median overall survival of patients with recurrent HGG; expectations regarding the potential benefits conferred by Orphan Drug Designation and Fast Track Designation; and expectations regarding cash runway and expenditures. The words &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;could,&#x201d; &#x201c;would,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;intend,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue,&#x201d; &#x201c;target&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management&#x2019;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; the Company&#x2019;s ability to continue as a going concern; expectations regarding the therapeutic benefit of the Company&#x2019;s programs; that final data from the Company&#x2019;s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company&#x2019;s ability to efficiently discover and develop product candidates; the Company&#x2019;s ability to obtain and maintain regulatory approval of product candidates; the Company&#x2019;s ability to maintain its intellectual property; the implementation of the Company&#x2019;s business model, including strategic plans for the Company&#x2019;s business and product candidates; and other risks identified in the Company&#x2019;s filings with the U.S. Securities and Exchange Commission (SEC) including the Company&#x2019;s most recent Annual Report on Form 10-K filed with the SEC and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company&#x2019;s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Investor Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Theodore Jenkins</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Vice President, Investor Relations, and Business Development</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">tjenkins@candeltx.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Media Contact<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Kyle Evans<br>Account Director<br>ICR Westwicke<br>CandelPR@westwicke.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Consolidated Statements of Operations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">(in thousands, except share and per share amounts)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">(Unaudited)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img160460863_1.jpg" alt="img160460863_1.jpg" style="width:624px;height:253px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Candel Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Balance Sheet Data</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">(in thousands)</font></p>
  <p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.009%;text-align:left;"><img src="img160460863_2.jpg" alt="img160460863_2.jpg" style="width:624px;height:199px;">&#160;</p>
  <p style="font-size:10pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.009%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img160460863_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img160460863_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #B ?T# 2(  A$! Q$!_\0
M'@ !  $$ P$!              <%!@@) 0($"@/_Q !:$   !0," @4&!0T,
M"0,% 0   0(#! 4&$0<2(3$("1-!410B87&!D14R.$*Q%B,S5G)S=92ALK/1
MTA<8&20U-E)7=)/!\"4T0U15@I*TX28W8CE38X.$P__$ !H! 0 # 0$!
M           #! 4" 0;_Q  R$0 " @$$ 0(% P,$ P$      0(#$002(3%!
M$U$B,F%Q@044,R-2D32AP=$D0['P_]H # ,!  (1 Q$ /P#:@
M       _):?K:C27'' 6/IW=DNKS*K3:M/I4BIQ)"OXO3G34IMK/F[R/DKQ]
M8OLRW<#Y"!Z-\(VSKM-CP;7:B4J=YTBI[5Y<\W.249[2XX\TBSP&;J+G3.+\
M-X?Y+FGK5L)Q?:65^">@ !I%,   ",];+NCVW0(K"JU(H<J9(0VU)CL$ZKGQ
MX'PP+]IJC53XYFZ;ZNS3]<46#7PYX](AW5QRXJA>]O4^C/T]R*E9.R(LE3*G
M."OC;5Y5C&?B\1-3".S;01\\<> R]/8[+Y^RPB];6JZH>[RS]P !J%$
MXW$KD9&.0
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M[^/)=J"O+'6)[O:+96LB,T9QR(7Q\X=6T]FG!%@AW%^J"A!17@JSENDY/R
M!,1@
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M\Y2EJ+6_BZ3\%O6WPC%:>M+X>VO)W  &^8H
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M()+AMGG)84?](BX\/2(YP49JZMMI>%Y^IU7+=!TVI)OR\\?0K.LNEIZG4%B
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MIKP_.2ZT(VI(O L#D &JNC.   ]
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MNP7P/VD7N(9#=<-\;33USOH9&._5P_*SM'[Q-_[=8VZ%_P",_P F?+^9&ZT
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M[1^\3?\ MUC(CKAOC::>N=]#(QWZN'Y6=H_>)O\ VZQOZ;_2O\F>_P"5&ZT
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M2?Y1B_?4?2+]-'HQDBO.SU'%GT643^1:?_9V_P TA[A3[=_D6G?V=O\ ,(5
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M 9?[F[^XN>E#V+-TGTRHVD-ATJT+?0XW2J:V;;/;*WK/*C49J/O,S,S]HO(
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M85;RDER^BZ@'E@RRG0V7R0I!.H)1)66#+)9XD/4)4\K*.6L   >G@
M                   =%-I4HC4A*C+EN+D.X !^4      !QM+P#:7@.0 '
M' <E\[@             #C:7@&TO <@ .-I> ;2\!R             XVEX!
MM+P'(         Z%Q[P4O9D?BXXVWEQ1X(N(@N[M5+AO7R=.FJ#F-1I:F*@;
MC1$9?T?C?-/SN)<> IW71J6>W[+MEC3T2MECI>6^$BM:I:KL_4O<$*U:@W)N
M&&DMS3'GN-IW$2U)+'$TD9\LX$;Z-T>K:PT>L4N[ES)E';4AV-+?,R=;>R>2
M0KO+'^>(DRPM!:7:MX2;B)YYV0\2E$RHR-MHU\5X/&3XF>,]QB5F8S4=*DH0
ME!<\)+ R(Z6[56JVYXCRMOAHU):FG2UNJE9;P]WE/Z%NV)8M,T_HJ:72TJ1'
M2HUJ4XK<I:CYF9^/ZA4FJ]3YDMV Q.87+;+SXZ74FXGUISD>=-U4>;4':2Q4
MH[L]"3)<=MY)K3ZRSG@(=L+H^U6U-3I%P2*JA^(EQQQO:2NU=WYX+SPX9/UX
M(7)3=>VNB.Z.</#Z15A6K%*=TMLL965V5VP="'K3U(GW.Y5ERFWE.*;9V8/S
MSR9*/)Y(NX2)=UV0;*HDJKU%2D1HY95M+*CSP(B+Q,\>\5Y2C;3S$$U;5^D7
M1J%(T^GT)4NG//>2..N*XFLBY[,<LESSGD8ZGLTL-L7AR?&>>6<0WZJ>^:RH
MKG''"+FM>BVAJA6*??D1IYR8S];1VBC3M4G/QD\LEG\HZZGZ@7+:]?HT"B4)
M53C3%[7G=JE;>)%C)?%X9/)^ NR/%H>FMIO=@RB!2X+:G#2@C/!%Q,_$S%.T
M[U2HFIT65)I:725%625H?1M46>1\#/P/W#W:MJKW*,GSQY.MSDW9M<HKA9\>
MQ<]2J4:D4U^;.=3'CLH-QQ:N2"(LF8HUCSK;K<*16;=3&6B6Y]>D,-[5+67]
M+AG/K\1YM3+HMRV;=>^J59>03/XN;>TU&YDCX8+T#UZ>TN@TVUXB+::;:I;B
M>U;[/.%9[SSQSZ_ 3*6ZQ033POR5U';5O::R_P %.K-0LV+>].34#AIN5:=L
M8W$_7<'W9QP%RUZ>FF4N3,6RJ0AAM3O9H3N4K!9P1"WZSI;;M<NR'<<Q@U5*
M+CLU=H9)/'+)9P>!=Y)2HUI,O,QR'D(S^-2267QC_DZE*&(.+;PN<_\ !9NE
M6HB=2J"Y4BI[U.)#JFNS>XYQWD>"%[X+Q$3P]:H:]3';+CTIYOLS-/E"2+&X
MBR?FXY>G(E;YNT=Z>Q2CC.6N&R.ZMPEEK"EREWP?J  +A 6!JUK;9^A]#C5>
M\JI\%P9+WD[3B6EN&I>,XPDC/D0BG^$8T&Y'>"_Q%[]D3)J)I9:>JU+8I]W4
M*'7H3#G;-,S&]Z4+QC<7LR-='2BT/L.S^F1I%:]&MBGT^@51<4IE/9:VM/[G
MU)/<7?DL%[!9T]==G$LY(IN2Z,XM)>EMI=K1<3M M&X#J-40RJ0;*HSC?F$9
M$9D:DD7,R]XF81MIWT==-M+ZP[5[5L^ET2IJ:-A4J*SM7L,R,TY\,D7N$DB&
M6W/PDBSY(SHG2$L2OZIU33N!6TR+MIZ%+D02:66W;MW%N,MN2W)[^\28-<&A
M9XZT;4C)X+9._P#\AL=[1/\ 23[QU.O:UCV.8RW++(WA:^614-6)FF3%92J\
MXS7;.4_LEEA.TEGA6-IF25$?,227Q5#79:OG=;17\<2\C7Q__B:&Q0<VU[,8
M\H1ENR6+JQK#:>B-MM5^\:E\%TQR0F*A[LEN&IQ1*42<)(SY)4?L$1_PC&@V
MW^=Z_P 1>_9%@=;/PZ-]*/O^J*/^@DBZ=">B7HY<6CEDU2IV#1)50F4>(_(D
M.L$:W%J92:E'Z3,30KAZ:G+)PY2W;42IHWTFM.M=JE4(-EUPZK*I[2'I#9QW
M&MJ%'@C\Y)9XD)8$>::Z$V!I/,FS+.M:G4"1*;2T^]":)!N(2>229^!'D2&(
M);<_"2QSCDA#4[IA:4Z/W:_;5U7(<"LL-H><CIBNN;$K+*3RE)EQ+P\1;U+Z
MPC0BHRVXR;V0PI9X)<B(\A'M/9@ABSK/9M%OSK2*90+AI[-5HTV-'3(AOIRA
MPB@+46?4:2/V#)^^^@/H?7[7GPV[.@T)Y32C;J,$S:<8419)9'G'#'(^' 65
M74DMV<LB4I<X\&0]'JT*O4V//ITMF=!D()UF1'62VW$GR-*BX&0J U^]4[>%
M8E434&T)$M=1HE$EM.07E&9H0;AN)6E)]R5=FE9%Z3&P(5YU^G)Q)(RW+(%B
M6/J_:NH=?N>BT"J(G5&VY90JBRDC+LW#+/#/QBX*+)=Z3(6[THM:(^A>B=RW
M4M2?+VV.PI[:C^R27/-;+V&>X_0DQK6Z(UT7/T:]<+%N2[2<CV]J1$5VLATS
M^N(<=,D.K,_G$X2%_<N>D25T[X.7^#B5FV21N& =4*)22,CX&.3Y" E(*U$Z
M:&DFEMV3+;N.YCA5B*2#>83$=7LW))2>*4F7(R]XZ6-TW=%]0*S'H]*O6*50
MD+)MEF6TY'[11]Q*6DDY]&>\89W/8% U*ZS&HV_<U-;J]'DQR-V*\9DE1IA;
MBS@R/@9$?L$K=,#H0Z2VQH9<ET6S16[4K-#CG,8D17EDEPR,OK:B4HR/.>'?
MG O>C4L)YRR#=+EKP9W)42N)'DAX:I5(U%I<FH3'.QBQFU/.N*+))2DLF? 8
M_P#0#U J^HO1IMR?7'%R)L5;D I#G%3J&S(DJ/Q/!D6?0)BU9_\ ;*[/P9(_
M1F*:AB>Q^Y+N^')"J>L9T&V\+P6?_P#"]^R*S9/3DT=OZZJ?;U$N=4JJU!WL
M8[*HCR=Z\9QDTX(8F=6CH-I[JII;<DZ[[3IM>EQZDEIIZ8UN4E/9YVD?K&:M
MK]%/2&SZ["K5%L2C0*I"<[2/*98(EMJ\2/Q%F<*JVXX>2.#E))DM[1'.JVOE
MD:+JI*;PJ_P8JJ.]C%3V2W#6K_E(\=W,2.->/6P8^%=*?[<K\Y(KUQ5D]K))
M2VQR;!HDAN9':?:5O:<02T*\4F62,6!>^O=CZ?7K0K0KU93!KM:42(48VEJ[
M0S/:65$1D63P7'Q%Z6Q_-ND_V1G\PAK_ .G+\LS1'^U,?]PD=UUJ<FF>.6%D
MV)<^)"']7.E5IIHC68U(O&OG3*A(9\H;93&<=R@S,B/*4F7,C$OM_8T^HA'>
MH71]TZU5J;-2NVTJ;7I[#78MOS&24M*,F>W/ADS'$<;OBZ.GG'!&'\(OH-Q_
M]7K_ !%[]D2=HWKY9.N=/J$ZRJM\*QX+I,R%&RMHT+,LD6%$7<9#7YH/H=8=
MR=/'4FS:G;%/F6S3V)2HM,<:RRR:76R3M+T$9^\QL7TWTCL[26'+BVA;T&WH
M\ISM7VX;>PG%$6",_80DMC7'B.<D<)2EV77*E-P8[LAY9(9:2;BU*/@22+)F
M(_TAUWLG6V-5I%F5A-69IKQ1Y/UI;9H499+XQ%DCX\?0+OO+^:%;_L3_ .C4
M,#^J%S\ ZGY_XE'_ $:AS"M2KE/V.I2Q)(V$CPU"H1J3!?ES)#<2*RDUNO/K
M)"$)+F9F? B'MW82HS/ UM],:_;HZ2?21I6@%H5!4&B1W4?";S1^:MPD[W5N
M8^,EM' D]ZO8/*ZW-X\"4MJR9&71UB6AUKU)Z J[%U%Q![5.TV(X\T1_=XP?
MK+)"4=)>D!I_K5#=?LRY(E66T1&[&29H?;SWJ;41*(O3C C;3_H":*6/;[5.
M>M"+7Y&S:]/JQ=N\ZKO5QX)]22(B'BL7H"Z>:;:U4W42UGZE1TPD.&BBL/F<
M8W%$:=V3RK;@S\S.,X/N'4E5A[6SF._/)D\+%U0U?M#1NW_AN\JW'HT$U=FV
M;QF:W5XSM0@B-2CX=Q>L7Q@QK'Z;3U+F=.:Q(&ISCR--DQXQD3AF3&Q1K[0S
MQW&Z226?/:0CJK4GAG4Y;5DRELWK"M#KNJR*:Q=OD#[BB2ARIQEQVE*,\8WF
M6TO;@9$1E,5!E#[)MOLN));:\$I*DGQ(R,NXQCY=O0IT+UBM>$J+;5+A1E(2
MJ+4[<-#"C1Z%M\%D?'GD3U;U!IUL4*GT>G->24^!';BQV49PAM"22E/L(B'<
MMJZ$=WDJP  B.RUKTLQN[X,:,N?,@$Q(1(W0W=AJVG\4_1^H5*CT*%14NE#B
MLQ^V5VCG9-DG>KO4>.9F*N..?(1>E'=OQR=J<W';G@Y'XR&S>86A*C0:B,B4
MGF0_8!W]#GKDQAT_Z/5PV_J:Q4YT]DX<5]3Y/-J,W'LF>",L<,]_$9.)+:1
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MR8+JIC%)C=FJ0L]INN*4:W%X[MRU*/'=D33:VK<^2./?'1(@  KDP
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M&32B^4O)9_3YP==E$XIN2X;?6#($!^32MR4GGB9=W^?6/U&]"6Y9,0  #L
M         #Z                  #\H          .<G[!P       ?,
M   #V\    #Z              /9@              >"I4>%68IQIT5F7'4
M9&;3R"6D\<N!CVMI)M.U)83R(B'; X(L#G:LYP>YXQDY  '1X<8QD1=KU*K3
M-HI8H=,CU9QYU+;L>0A*RV<>)),R(^.!*/>(FU8M=B[J_;$&33*K+93(-PY4
M%1$VP9%S<SX^PQ2U$92J<8]O@LZ5QC8I/I<EUZ;4?X#M6$PJG1Z8[V25/18R
M22A"SY_YR8N\=&D$VE)%X8'<3TUJN"@O!%9)SFY/R  !,1G4DX4(CZ1%H1J[
M9YSIDR9&8IJO*5)B():G"+NP9D6? ^X2\/-*CE*CN-&>"6DTYQR%:ZI60<7Y
M)J;'7-37@H.G-49K5FTN9'1(0PY'2:$RB^NXQ\[TBYOFBVK'MN3;%'.%+JDB
ML.]HM?E,DBW8,\DGAW%R]@N1OB@^ ZI4HUI2[/+'&4Y./63L  )R(
M
M                             (^*8 .&%T  !V          #Q   #T
M
/                '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img160460863_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img160460863_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %! Q<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MME_\D4?\)7??]"?KG_?VR_\ DBK]%'LT'MI%#_A*[[_H3]<_[^V7_P D4?\
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M.9YWM2B\9Y"3,W/3@'K^-:OVV/\ NO\ D*HT4>S0O;2->BBBL#J(;K_CV?\
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M7@2X,D6+EID90J '(W,VYBX7E1][K70WGA>YD%^(].B._P -KIT7W!^\^?\
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M278AHJ;[+-_<_44?99O[GZBCF7<.278AHIM\YT^SDNIHIWC3&1!"\SG) X1
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MU*._GTK7VG1D?C2=05&9>59D$>URO8L"1@8Z5<?6M)?4(K]M.UPW,43Q(_\
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MR<M659>/M<U?4M&TRT@TZVN;J2_M[J2:-Y$62W( 9 &4E3Z$YYZ\<KVDN_\
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MEV#VD>Y9HJM]MC_NO^0H^VQ_W7_(4<DNP>TCW+-%5OML?]U_R%'VV/\ NO\
MD*.278/:1[EFBJWVV/\ NO\ D*/ML?\ =?\ (4<DNP>TCW+-%5OML?\ =?\
M(4?;8_[K_D*.278/:1[EFBJWVV/^Z_Y"C[;'_=?\A1R2[![2/<LT56^VQ_W7
M_(4?;8_[K_D*.278/:1[EFBJWVV/^Z_Y"C[;'_=?\A1R2[![2/<LT56^VQ_W
M7_(4?;8_[K_D*.278/:1[EFJFH?83;*-0-MY1E0)]IV[?,W#9C/\6[&.^<8Y
MIWVV/^Z_Y"HKI[*^M9+6[MEN+>5=LD4L8=''H0>"*.278/:1[G%6DEOIMSJT
M^K6W]H:M%K(:U6U0QK<W#6R!?+C+$*0A()9F PS$CL6FDKH^NZ3%K!M]D]KJ
M=U*G'DQRR/&[HN>H"&09/) 8\9(KI)=#\,SV$%A-X?TZ2SMR6AMWLXS'&3R2
MJD8&?:G-HOAQ],336T'3VL(W\Q+4V<9B5^?F"8P#R><=Z3@VK>5OPM_P?DA^
MTC??^OZ_43P1YO\ P@N@^=N\S[!#G=U^X,?I6]587D0& K ?04?;8_[K_D*J
M2DVW82G&VY9HJM]MC_NO^0H^VQ_W7_(4N278/:1[EFBJWVV/^Z_Y"C[;'_=?
M\A1R2[![2/<LT56^VQ_W7_(4?;8_[K_D*.278/:1[EFBJWVV/^Z_Y"C[;'_=
M?\A1R2[![2/<LT56^VQ_W7_(4?;8_P"Z_P"0HY)=@]I'N6:YOQ4@U*XTK0&S
MY%_.6N@#]Z")=[*?9FV*1W#$5M_;8_[K_D*C:6T>XCN&@#3QJRI(4!90V,@'
MJ <#/T%')+L'M(]SG/$.EVJ>-/"VI8D:Y-[)"I:5BL:?9IB0J9VKD@$D#)P,
MG@4K:9;6?Q3L[R/S6N+K3+KS7DE9^!)!M503A5&3P,#DGJ2:Z*26TFDBDEMP
M[PMOB9D!*-@C*GL<$C([$T&6T:Y2Y:W!G12BRE!N5202 >H!(&1[#TIJ,DT[
M=_Q0W4B^O]7+M%5OML?]U_R%'VV/^Z_Y"ER2["]I'N6:***DLANO^/9_P_G6
M=6C=?\>S_A_.LZMZ>QS5OB"BBBM#$**** "BBB@##\5SS6VE6SP2R1,=0LT+
M(Q4E6G0$<=B"01Z&LR/Q?J$\L832(4AN+FZL[>5KP[C+")""R^7PA\L\Y)!_
MA/6NCU+38=5MHX)VD54GBG!0@'=&X<#D'C*C/M5*+PS91+9J))R+6[FO$RPY
M>7S-P/'3]ZV.AX')[RT^5I?UL6G&VO\ 6_\ P#G(?'-QI_A?0)M2_LW^TM0L
M_M!:[OQ;0LJJN3O*8WMN7Y N.O.!DWT\<QS"2ZAL2=,ATR/4IYWEPZQN'(54
M"D,WR=V YZU;B\(Q6VGV%M;:KJ,$MC&T,%TAB,JPG&8SF,J5^5>2N?E'/7-L
M>&[ M=^<9YTN[..RF2:0ONC3?C+'YBQWMDD^E.5W=K^M_P#@?\,'N_UZ_P"1
MA6GQ BN=.U.98+*>XL4BE(L;\7$.R0[07D"#9M(8O\IVJ,\T'Q/JM]-X?>QC
MTXPW6H26\[6]^)XI46)V^1Q&2>A/(4[DQT.ZMJ+P^Z64\$FN:M-+*$"W#3*K
MQ;3E=H153KURIW=&R.*@C\(6T8BD_M"^-XE[]N:[)C\R239Y9W )LP4^7 4>
MO7FCJ+2WW_E_F3^)?$4/AVSMY9#;"2YF$,1N[@00@X+$O(0=HPI[')P.]9:>
M.X3H]GJ[V8;3YC)#)-!-YNR=6*A%P/G5V!"N#R2O SQOZKI4>J10@SS6T\$@
ME@N(-N^)L$$C<"IRI8$$$8-4W\+V=RMNE_<75_%#'(OEW3AU=GR&D88'S8+
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MG?7[N%4-=.GRJ.@"HJKW.3C)[DX&-&J(>X4444 %%%% !1110 4444 %%%%
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M#O-<LS=P71TR74;);74(IK8NVT9X7YAM8;G&X[@<@X.!4N_3^MRU:VO];?\
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MCU2Q:"T)%U(MPA6 CJ'.<*1WSBHU\3: ]@+]-<TUK,LR"X%W&8RP&XC=G&0
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M025R>F >U^Q\*ZO9W]MOA,L<.IB8S&53NC&GB'?USS(,8Z]\8YHZ/RO\]?\
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M*.W$LK0OM 43$1C(Y/'THM':P7G:]_ZU_P CV+[;)_=3\C4%SK,5F(S=3V\
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MD<U=_"X7L&B6\NJ1&/3+>VA$HL5%P#$1S%*&#(&QR&WCTP>:N77P[2ZT37[
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MEBO9KBZU)98Y!=QL)/D#[O-.YG5RK*%4J<9PN<C_ (0S7O\ H9W_ ._VI?\
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MU*J0N@=>%+_,J[>3]T@$9Z5T'E2?\\W_ .^34']G)]N^V&!S<"/R@YR<+G)
M'09.,XZX&>@IK3K_ %K_ )_<2]5M_6G]>IYEXMFT^#XEW#ZEJ<^G0CP\2LT-
MPT!W^<V!O7!SZ#/)XP>E8^K^(-6DT>RAU#4;K3]3705NE,EU)#Y\YS@1QQ[2
M\G R&8@9^X>:]L\J3_GF_P#WR:/*D_YYO_WR:GETM?\ K7_/\"^;6]OZT_R_
M$\6N_$&K?VAX;OY-7GN1<65D[65K<O;S-(Q^9D0KY<ZG^(<E1_=ZU>;6-0WZ
M@MWJ5W%I0\4R6]Y<"X=3!;B,%5#@YC3?C)!&,]1FO6_*D_YYO_WR:/*D_P">
M;_\ ?)IZ7O\ UNG^EOF2KVM;^K-?J8/AR>S?0/-T[4+W4[57D\N>X)=V )X5
MB 74= QSGU->:^&O$=Y<^+_#KQ:Q+)'J'VH7EI+=R3O&0I*+(#B.-\J<*B)P
M#U%>T>5)_P \W_[Y-'E2?\\W_P"^30U=WN&MFK'C?A;4=51/!-V-3O[FXU);
MZ.X2YNWD278&*?*3@$$#D#..I-1:!>K?>)? LUQJ5U=:LTMX=1BGF9S!-Y;9
M4H>(L= HQP,XKVGRI/\ GF__ 'R:/*D_YYO_ -\FGI>XW)N^F]_QO_F</XPO
M6@\4:#;W]_/8:)*LYDFBG:$/. /+1G4@]-Q"YPQ'0XKDO!=[<PV7@""&ZG2"
MXN=2$R!BHE \PC>O&<'GD<&O9?*D_P">;_\ ?)H\J3_GF_\ WR:5EW"[M:W]
M6:_4\8\+:I)I5AX(EFOGM--DN-2CN"TI2)G+L8P_."<@XSWZ56T6XDO+KP/J
MNH7UP\K_ -HQI-<7DB;Y!(?*0DL.O V_Q 8((&*]P\J3_GF__?)H\J3_ )YO
M_P!\FBWF-ROT_K7_ #/'/!^L:]=ZCI;-J<;ZDZS_ -HV<U_--(Q . T'E;+;
M#;<'<H/3G-0Z!>K?>)? LUQJ5U=:LTMX=1BGF9S!-Y;94H>(L= HQP,XKVGR
MI/\ GF__ 'R:/*D_YYO_ -\FFK7N)MN^FXRBG^5)_P \W_[Y-'E2?\\W_P"^
M33NB+,913_*D_P">;_\ ?)H\J3_GF_\ WR:+H+,913_*D_YYO_WR:/*D_P">
M;_\ ?)HN@LQE%/\ *D_YYO\ ]\FCRI/^>;_]\FBZ"S&44_RI/^>;_P#?)H\J
M3_GF_P#WR:+H+,913_*D_P">;_\ ?)H\J3_GF_\ WR:+H+,913_*D_YYO_WR
M:/*D_P">;_\ ?)HN@LQE%/\ *D_YYO\ ]\FCRI/^>;_]\FBZ"S&44_RI/^>;
M_P#?)H\J3_GF_P#WR:+H+,913_*D_P">;_\ ?)H\J3_GF_\ WR:+H+,913_*
MD_YYO_WR:/*D_P">;_\ ?)HN@LQE%/\ *D_YYO\ ]\FCRI/^>;_]\FBZ"S&4
M4_RI/^>;_P#?)H\J3_GF_P#WR:+H+,913_*D_P">;_\ ?)H\J3_GF_\ WR:+
MH+,913_*D_YYO_WR:/*D_P">;_\ ?)HN@LQE%/\ *D_YYO\ ]\FCRI/^>;_]
M\FBZ"S&44_RI/^>;_P#?)H\J3_GF_P#WR:+H+,913_*D_P">;_\ ?)H\J3_G
MF_\ WR:+H+,95'68[Z71;V/3)!'?- XMW..'QQU]ZNS[K>WDF>*8I&I=A'$S
ML0!GA5!)/L 2:YV_UK2M3T^>QNM/UUH)T*.!HEZ#@^A$7!]Z4FK#BG>]BIX(
MFB_TVV:?5ENU=FDM-1G:8QJ)'565R6!R%P=KD KT!))ZZN)T!].T2:XN9'\3
MW]U/D&:YT.Z!5-[,% 2 #JY).,DGTP!N?\)18_\ /EKG_@CO?_C5',K;@X2N
M[(VJ*Q?^$HL?^?+7/_!'>_\ QJC_ (2BQ_Y\M<_\$=[_ /&J.9=PY)=C:HK%
M_P"$HL?^?+7/_!'>_P#QJC_A*+'_ )\M<_\ !'>__&J.9=PY)=C:HK%_X2BQ
M_P"?+7/_  1WO_QJC_A*+'_GRUS_ ,$=[_\ &J.9=PY)=AWB:]ELM%80.\<]
MS-%:1R(,F-I7";A]-V?PKFKZXNH[[4-12^O%.F:I:6,,(G;RVB<0A]ZYP['S
MF^9@2,+@\5?\0ZQ;:GHTL,%EK?VF-DG@!T2] ,D;!U!/E="5 _&JLK:1>ZJN
MIR0>*(1(\5Q/8C1;KRI)8Q\C/^X)W+\OW6 .Q<YQ24E>_P#73_@_>4HNVQT7
MB&".6P66ZU.33]/@;S;MXI&B9T /R^8I#(,X)(Y.,=ZXQWU)K+2[:Y?6IXY5
MNYH;2VN7BO#"&7R9)),J?E5L%6;<2RY#$&M36)K'64MQ+<>*X?L]S]IC,6@S
MD!A]T$-;,"%ZC(SG!SD##+E[2ZCMF>^\7K>P"1%ODT*9961\;D(%KLQPI^[D
M%1S4MIW_ *_K_A[;C2:MI_7]?IV+>BZC=_:/#S2WWVV/4M,S)* 0K2H%8.JD
M#&X,^>!T' Z5UM<-;7EC:ZSIJP:;KL6FZ79-#;@Z+>,79MH_YY9^54ZGKO\
M:N\\J3_GF_\ WR:TYD]OZU_KY$.+7097'^-HM0,EA+&=1.FJX2==/N3#(':2
M,!CM969=OF# )Y8<'J.DU+48M*\K[1;W[^9G;]EL)[C&,=?+1MO7OC/..AKE
M=?DT[6W@GC;Q-8746%$]MH=T2R;U8J0T!'500<9!'ID&9-#C%WV.JTF>"ZTB
MSGMKJ2ZA>%2D\HP\@Q]YA@8)[\#GL*N5SFG:SI6EZ=;V%K8:\L%O&(T#:)>L
M<#U)BY-6?^$HL?\ GRUS_P $=[_\:JG)7W%R2[&U16+_ ,)18_\ /EKG_@CO
M?_C5'_"46/\ SY:Y_P"".]_^-4N9=PY)=C:HK%_X2BQ_Y\M<_P#!'>__ !JC
M_A*+'_GRUS_P1WO_ ,:HYEW#DEV-JBL7_A*+'_GRUS_P1WO_ ,:H_P"$HL?^
M?+7/_!'>_P#QJCF7<.278R_$>LW5M<ZU):RNATC26N57^%Y9-^TL.^T1GC_:
M^E3Z!'+IOB*^TG[9=W4 L[>Z5KJ=I65V,B/@L20#L4XZ YP!FJ-UJ%C-K\\S
MZ7KDUEJ%C]DNU.BW@QM+%>/*S@B1P<>WU"Z9+I^EQW!2;Q7/=3K&ANY]$N6D
M5$^Z@Q;A<#+=02=Q).:2DOZ^?_ *E%VLE_6G_!^\E\30SV&I66H0W.IAYKV"
M-IOM)%K;(752C0@@-OR0"58@MDLH Q2LKJ[;4]/U5[VZ9K[5[JPE@,S>2(4\
MT(%3.U6'DJ=P&3ELGFK5S/IUWJ!GFD\5O:M*DS6+:-=-"73!4\P%U *J=JL%
MR.G)S' ='MM9.HK%XG=5EDN(K-M%NO)BE<8=U'D;LG+=6(&]L 9H377^MO\
M@_TV-IVV_K7_ ('W&[X9NI[C398;F0R36=S+:F1CDN$8A23W)7;GWS6S7->#
M;CS;.2%[34HKR>26\F%SIT\"H7?.P.Z!25!"\$YP3TKJ/*D_YYO_ -\FFGHK
MLAQ=WH:E%%%<QVA7FVN?$+5M(A\3VL=G:SZK8W]O:Z; $8"<3@%-PW<G[_((
M!V]J])K@-7^'UQJ7Q6TWQ.+B$:9!&C7%LS'>\\8<1L!C! WCJ>U*UVE_7]=/
MF.]DV,T7XA7&K7?AY62S@@N-*FU#57DW#[/L(3"DGY1O#YW9X%;R>,](U#3[
M]],OD^TV]HUTJW=O+$"@!Q(%*AGCR/O(#[5R6D_"FXM7\90W=_%]FUB-[?3S
M%N9K:)V=R""!_$X. ><=:LZ9X!U*."Y^V)9K<C29-/@E_M.\NBS.,$_O3MC3
M@?*%;V/&"2=XOO;_ #=OEH@22E;I?_+_ ()O0>.M(M='TV?5M0A^TW.GK?2&
MSMYGC6/:"TF-I9(\G@OCTZUG7/Q(L[7Q3##)(&T*;15U1+B*TFDEY<C)"@D)
MM&3E1CN17'ZS;'P6OV274],2]G\*K831732H&:(%0T#;-LA)8CR\JW0UO:-X
M*U66QLKMS!!YGA%-),,I82).1GYACA1G!YS[54MW)=+_ /MW^2^\26B4NMO_
M &V_YLZ0>/=(;Q-_8_[[R_[/&H&],3>0(SR"7Q@+M!.XD#MG/%7-/\8Z!J8G
M-OJ 7R(/M+_:(G@_<_\ /4>8J[DX^\,CWKCO^%;ZFT$-J]Q:>3/X:31;J197
M#1.N2)$79\ZYQP2O'Y4MK\-KVZL;NVU0V\#OI3Z?'<1ZC=WCY;&6 E8*B?*/
MD /^\*):7MY_K;]/O!=+^7Z7_7[C;TOQS'K?CJ#2=/VOILNE-?>9+;RQ2EO,
M55P'Q\A4Y!V\]C6SK'BK1]"F\F_N9%E$1G9(;>28QQ#@NXC5MB]?F; X//%<
MWI7A3Q%_PDUMJNI7%A9B'1#I@;3Y#)(K[U/F+YD87&!T(..GS57\3^!M>UBX
MFB^WV^J6<VG-:+_:<IC-O*2V9A'%&(W;! &0I&T<]<J6B5O/\W;] 6KU\OTO
M^IU3^+]!C2^=M00)96J7D[;&P(7!*NIQ\X.#]W/IUJ.Z\:^'K*[%M<:ALD C
M:0^3(4A#XV>:X7;%G(QO(ZUR=[\-+Z]M/"T7VNV@^Q6D-CJR(S%;F",HX5,C
M)^=.^.&/TI=9^'-]=Z[K<]N;:XLM9>-Y5N-1NX!#A0K Q0L%F! R,LN.F<4[
M*_W_ -?-"6VO]?U_D=>_B[1(]7N]+:\875D@>Z_<2>7 I3>&>3;L4;1G)..W
M7BFV/C'0=1:=8;UHS!;_ &I_M,$EO^Y_YZCS%7<G'WAD>]8Z>$=4@U#QA<6=
M_%:-J]O!%8S1LQ>!HX2FYLCCGD$$G\:Y=_AS?QG5+_4QIUE;S>'Y=/G:REGN
M92^0WG$E TA.#D<G  R:ENR?I^C_ . BDKM?UV_X)W=AXZ\.:C<&"#4&606A
MOB+BWE@Q;@X\S+J!MYZ]QR.*LZ/XJT;79V@T^[9YEC$HCEADA9XR<!U#J"R9
M_B7(]Z\LTJUE\>:[);"\L)+9O"IL'NM-=I8XG=UV[MRH58X)\L@$ 8-=GX2\
M'7VDZM!?:E%;"2ULOLL<B:E=W;ODC)'FD+&IVCY K<_Q#&*NROK_ %J_\E]Y
M-]//_@+_ #9OZSXKT70)A#J-VT<GE><RQP22^7'G&]]BG8F>-S8'!YJ*]\;>
M'=/NVMKC4T#HJ/*\<;R1PJ_W#(Z@K&".06(S5'4M#UVV\676O:"VG227EDEI
M)'?O(HB9&8JXV [A\QRGR]/O"LG5/!.O3-XEM;.YTU[3Q$J?:9IMZ26S>6(W
M** P<$#(!9<>IJ%M_7?_ "ZE:7-^_P#'OAK3+N[MKS43')9R1QW)%O*R0F0
MH78*54'(^8G'O0?'OAI+"]O9=0:&&Q:-;GSK:6-H_,("$HRAMK9X8#'O7,:C
M\.-2GTSQ796MS:;=5:Q^RF5VRJP! V_"\$[3C&?PJ3Q%X U75[OQ/+;W%DJZ
MK_9_D>8[ KY#9?=A3C/;&??%4K:?+]/^"3K:YO2?$7PO#)<1RZA-&ULX2X#V
M4Z^1G&UGRGR*<C#-A3V-6]0\9^']*OY+.\U )-$%,Q6)W2 -]TRNJE8P>VXC
M-<SX@\!:IJR^-Q!<6:_VZMJ+7S'8;/*4!M^%..G&,_A2ZIX(UN1_$MII]QIY
ML?$03SY;AG$MJ?+$;;5"D2 @9 )3'O2_K\O^"597.AO_ !UX<TV^NK.[OW2:
MT:);G%M*RP^8!L+N%*J#D<DX[9K5U75['1-/:^U"X$-NK*N[:6+,QP%55!+$
MDX  )-<#JOPYU*YL/%]I:7-H$U>"SAM#*[ J(453YF%XSCC&?PKK/%F@MX@\
M,2Z8+:RN2Q0^5=LZHVU@3AT^9#QPP!P>QZ4/;02,74?B):Q:QX;%@ZW&EZF;
MI9G6VE>=6B4858U&X-N)!!4GCM6W_P )GH!TVQOX[UYX;\,;5;>WEEDE"_>Q
M&BE^._''?%<UHW@;7++4O#-W?:E'<KI<EXSK+.\KHDJA8XT<J"X7'+-M^G:J
M=IX \0V.B:)8^;IM[#9O=FZL9KF6."8RR%HW)5#OVY^ZRXY//>A[:?UO_7]7
M#S_KJ==)XY\.QP:9,+]YEU-7:S%O;2S--L^\ J*3D9Y!&>OH:D'C+0&U;^S1
MJ ^T>=]GW&)Q%YW_ #R\W;LW_P"QNW>U<GX8^'NJ:&?!ZSSV++H9OO/,3/\
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M9C(%=XGMB%#R1L,<#:V&. <>I KJ_&N@:CKT&C'3)+5)K#5(;UOM+,%94#9
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M)(]A"%50,DD[> !63<6/PUMM/L+U_#^C/#?Q^;;"'1A*\B;0Q;8L98* 022
M!D9QFNIO[?3=9L)H9X[:]BA<[D<+(JR+ZCIN!]>AKA+:>STSPEX.U677+?2;
MF/21"CW4!DCEC:.-F0?,H$F44KR<X;Y6YPKZ-^GZ_P"0[&AJEG\-]'A\^\\,
M:?\ 9O)$YN8/#[3PB,\[C)'$RXQSUK2NO"O@:RTN34KCPQHL=K%%YSL=+CR%
MQG[NS=GVQFLC3K&8Z%X(\.7J.N8UNKJ*08;;"@948<=)&BS_ +M;_BZ2PNM
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB'_T"?\ RF6__P LJ] HH \__M;XA_\ 0)_\IEO_ /+*HTOO'T<\LZZ/B27
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img160460863_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img160460863_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #> K@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%5KK4+*Q_X^[RWM\1O+^]E"?(N-S<GH,C)[9%
M%FJ6KM"FC7K7%])8PB!S)=1L%:%<'+@D$ @<]#4T5[:37#6\5S#),J+(T:2
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M,#!&1Z&EM--MK*[O;F%<2WLHEF; &2%"CH/11UYIWZ?UT_X(=;_UU+=%%%(
MHHHH ***K?;8_P"Z_P"0II-["<DMRS15;[;'_=?\A1]MC_NO^0I\DNQ/M(]R
MS15;[;'_ '7_ "%'VV/^Z_Y"CDEV#VD>Y9HJM]MC_NO^0H^VQ_W7_(4<DNP>
MTCW+-%5OML?]U_R%'VV/^Z_Y"CDEV#VD>Y9HJM]MC_NO^0H^VQ_W7_(4<DNP
M>TCW+-%5OML?]U_R%'VV/^Z_Y"CDEV#VD>Y9HJM]MC_NO^0H^VQ_W7_(4<DN
MP>TCW+-%5OML?]U_R%'VV/\ NO\ D*.278/:1[EFBJWVV/\ NO\ D*/ML?\
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M@9(VE< G&*JZ)!XX.EZE*E_JYU?^S)O-@N+*9(Q<Y^78\TK(6X;;Y*!,'G'
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MHNH-:TP1Z?J#Q7%E<R/8")%F\Q'C')9@HP"_.[!R,;LK4-KX%>STN^LX;G3
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M-')+-/>2E-N9')<E!N^4;F/'S<=\C)GTK3/[,2[!F\U[FZDN6;;MQN/ ZGH
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M04*^M_+^O\RHN*:OW*WB^[U+3-.;5+?59[=8XAY-O%:*\;R\G,[LIVQ] 3E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.[%:FDZM%JT4Q$$UM<6\GE7%M<;?,B; 8 [2RG*E2""1@UP=MI0O#J^HW/\
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MD=E)%&L:1[44!5&1P!7,W'BK7-+M[ZUU!-.DU)%LWMY(D=($%Q)Y0W@L2=C
MDD$;ACA:WO#VKSZA)J=C>26TMYIMR+>:6V4I')E%<$*68J<-@@D\@\T>T?\
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M^^C1[)A[==C4HK+\V3_GH_\ WT:/-D_YZ/\ ]]&CV3#VZ[&I167YLG_/1_\
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MSXO&>D2VEU<F^FBCM55Y5G@EB<*W"D(ZAF#'@8!R>!DUH:?J\.J6WVBTGE9
MQ1ED1XW1AU#(P#*?8@=13]F[LGVR2V_K_AC?HK+\V3_GH_\ WT:/-D_YZ/\
M]]&CV3#VZ[&I167YLG_/1_\ OHT>;)_ST?\ [Z-'LF'MUV-2BLOS9/\ GH__
M 'T:/-D_YZ/_ -]&CV3#VZ[&I167YLG_ #T?_OHT>;)_ST?_ +Z-'LF'MUV-
M2BLOS9/^>C_]]&CS9/\ GH__ 'T:/9,/;KL:E%<KJGBG3M&G$-]>3(^SS&V1
M22"),XWR%00BYS\S8'!YX-1WOC#3M.N1!=2Z@A:1(ED%A<-$S.0% D"%#DD#
M@]:7L_,?M?(V/$-C<:AI?V>&PTS4%:13+::D#Y4J#MD*VT@X()5NF,#.1DCP
MK<K\/M2T))+87U]%<%F7*Q))*6.!QG8NX*..@'':KNHZO%I5H;J[FF$>Y4 C
MC>5F9C@ *@+$DGL*BE\06MOHLFKW-Q/;V4:&1WN(I(F4#U1@&'TQD]J%3WU&
MJ^JLBEXA\+7]Y<ZA+IT6G2G5-/73[EKQF!A4;L.F%._[YRA*C*KR*ZV"(06\
M4(8L(T"AFZG QS7-ZCXFT_29H8;V]DC>8!AM1W"J2%W.5!"+D@;FP/>M:*60
MRH"[$;AWH]F[;DJJM-/Z_I&E11169N%<1XQ_Y ]K_P!A.R_]*(Z[>JGV'_II
M_P".UI3DD[OR,JD6[6/-/&-_]GU34%N-4NK*6+3EDTB.&X:+S[G<^0%! F;(
MB&PAA@]/F-4VNK72HO&#3W5U#=R7L!E1+YHS&LD<(#%FSY4>XL#(!D*./NJ!
MZO\ 8?\ II_X[1]A_P"FG_CM4I1[_P!7(Y9=OZ_K\SR'P_>RW>LV"-<^=!%K
MC"#%])>*$-BY^2:0!G4G)!Z=<$BNE\675M#J^GQ:MJ<VG:0\$[--'=M;!IP4
MV*9%*G.TN0N><'@XKN?L/_33_P =H^P_]-/_ !VFY1:M?^K6%R2O>W]79XK.
MSOIVNW&ISSIJMUX5AD,<TS*9"%E#GRB=N1\N0!\I8]-QSLZG+J6CC7+2QO;N
M9$MK&9VN+I_D$DKK,X?YC$-BY^483!*@8KU'[#_TT_\ ':/L/_33_P =H<XL
M?+/M_6G^7XGE%A+=WZ:7:'56>PN-7>-&L=3GGS$+9W*?:2$:0;P>03C[N?EP
M.G\3$KJOAL@D$7LN#G_IVFKL/L/_ $T_\=H^P_\ 33_QVARBU:XN25[VZ/\
M&_\ F>(ZQKTW_",Z?_Q,;M=2308KA#)JTEL7D92=\:(I-P^5^8-\H&.F2:T;
M^^ABUS6)8=4GBUMYK,V-M'.RK.Q2/=^Z!Q(".&R#M'/R]3Z[]A_Z:?\ CM'V
M'_II_P".T.<6[W!PEV_K3_(\<OKZ\%I=78NI_M,6G:WY<WF'>FVY4+ANHP
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M_P!>K_X!S]Q\1-3U"VEATN'1VO(+FQW26FJBYA*33;"A<1?*V1@C;P&W D@
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M>VOX+ZZ:V\^WG5U0K$\AY7()^3&,CK5[4-6T[2(DEU+4+6RC=MJO<S+&&/7
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M:J_VMD8Y*(5 C4_1 N??--:_U_7F0UI<WJ***8@HHHH **** "BBB@ HHHH
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M/LP5 .X,5&X9(P<0V?BN0>(;[3[J&Y>=YH5MK!$C,L2F)&D+$';M4MDMN(Y
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MM\O/(!XP%P<]?14V7]?-?JQW_K\?T//]:^&0UBUBMGO[1T738[#?=Z>)WA*
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ML3MV =/3-=)10M+#>H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cadl-20240514.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-13T17:57:04.5930+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.candeltx.com/20240514" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cadl="http://www.candeltx.com/20240514" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cadl-20240514.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139795025816816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CANDEL THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001841387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 14,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-40629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2214851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">117 Kendrick St<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Needham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">916-5445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CADL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #E0:Y899!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ Y4&N6)E<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #E0:Y8UN89&X4$  #,$0  &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ Y4&N6)^@&_"Q @
MX@P   T              ( !R0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #E0:Y8EXJ[',     3 @  "P              @ &E#P  7W)E;',O+G)E
M;'-02P$"% ,4    " #E0:Y8'#AEZC\!   \ @  #P              @ &.
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Y4&N6"0>FZ*M    ^ $
M !H              ( !^A$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ Y4&N6&60>9(9 0  SP,  !,              ( !WQ(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  *10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cadl-20240514.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="cadl-20240514.htm">cadl-20240514.htm</File>
    <File>cadl-20240514.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cadl-20240514.htm": {
   "nsprefix": "cadl",
   "nsuri": "http://www.candeltx.com/20240514",
   "dts": {
    "inline": {
     "local": [
      "cadl-20240514.htm"
     ]
    },
    "schema": {
     "local": [
      "cadl-20240514.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cadl-20240514.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cadl-20240514.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security 12b Title",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.candeltx.com/20240514/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000950170-24-059109-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-059109-xbrl.zip
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M8I-ITM":W(6[RINQMG+UW6^4Y"R3@[L7\#\UY^B5M>,;."M<6F6U&JR-M]\
M5NH3]+>$#(IZF=K2893'6(R"X"_2Z!7]^T>Z3Q#U7+E@U>,4+;V8AN6L>.A
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MTA4!'D$'<R)9T;-F"HCR\TI9_.1Z^JEEI4@=JTSR'^P;\=&Z148J6S/8_BO
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MF$$GT.N5UOJY+\JK4\Z;JTIK_4YLE&TG>[->B:S3+5T.GO!!*3;6"5B5F2?
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M/SHZ>GWT^V6^ L0MP#D0M8$ :9 0K8^!HH3%S C]!$!*_ME82:)GBG8IC?/
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MK$+@* 6-0C(2ZO"R'X+%7S;RRHKKE)7& 55!QJCI($]#/119"@<*#*?1>*3
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;,2YH=&U02P4&      ,  P"[    UC8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>cadl-20240514_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cadl-20240514.xsd" xlink:type="simple"/>
    <context id="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001841387</identifier>
        </entity>
        <period>
            <startDate>2024-05-14</startDate>
            <endDate>2024-05-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_453f6126-d104-4821-863e-978d8da3f7f8">0001841387</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_0a59e04b-f099-449e-912f-08e8847957d4">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_43950711-2afa-4c57-ac76-6efba40993c0">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_e3e1bcc5-28ee-45b6-b282-62743ec17d80">2024-05-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_224be1f4-0e1b-46d7-80bd-3ca5e22e1f78">CANDEL THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_f2f1d5f5-8cff-4007-9e16-a6ef712df647">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_91814a79-7a63-4182-b028-585539629491">001-40629</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_123855ef-0475-4dcb-a756-b8888994bf8f">52-2214851</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_cf298595-4374-48d9-811c-d5790679fb58">117 Kendrick St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_d6d16703-1c40-478c-aad5-f8a0975f724f">Suite 450</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_869e7d2d-9fd8-4c27-a85f-ccf8d6e88b8a">Needham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_5ce5fa7d-209d-4b74-b575-36afccb79b15">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_1c2b4fc5-b604-42e5-a9b3-cd0849879894">02494</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_e639482b-4c3e-4915-b0e8-e110dcdc3be1">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_7618bd8b-e01b-406c-b16c-bc08f3f91b57">916-5445</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_aaab7e50-fe35-489c-9431-2e671a30291f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_e5f95926-75b2-4412-bee1-5a11e6590cdb">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_0374c72c-17c3-42fc-8f17-04f79edae212">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_063edc3f-39db-4dfc-98e0-f7dd390b25d6">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_c58d815a-2eea-43a3-b229-65227ac33819">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_55735ef1-9a82-4523-9f7d-f80e662b9cdc">CADL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_055c397e-4c85-4e37-b2d3-d1c73973adae">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_f6cecfc3-dc62-4683-80d3-3b77b285e224">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_d2d6950d-fcf3-49fc-82fe-2935a1cd4c5b"
      id="F_8f6e3358-f5c2-4154-a4c2-025bb5b64a58">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
